The stock of Achaogen Inc (NASDAQ:AKAO) is a huge mover today! The stock increased 3.45% or $0.17 during the last trading session, hitting $5.1. About 78,626 shares traded hands. Achaogen Inc (NASDAQ:AKAO) has risen 27.06% since April 22, 2016 and is uptrending. It has outperformed by 21.65% the S&P500.
The move comes after 9 months positive chart setup for the $142.61M company. It was reported on Nov, 25 by Barchart.com. We have $5.51 PT which if reached, will make NASDAQ:AKAO worth $11.41 million more.
Analysts await Achaogen Inc (NASDAQ:AKAO) to report earnings on March, 21. They expect $-0.47 EPS, up 22.95% or $0.14 from last year’s $-0.61 per share. After $-0.41 actual EPS reported by Achaogen Inc for the previous quarter, Wall Street now forecasts 14.63% negative EPS growth.
Achaogen Inc (NASDAQ:AKAO) Ratings Coverage
Out of 4 analysts covering Achaogen (NASDAQ:AKAO), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Achaogen has been the topic of 4 analyst reports since March 16, 2016 according to StockzIntelligence Inc. On Wednesday, November 2 the stock rating was initiated by Aegis Capital with “Buy”. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Outperform” rating by Wedbush on Tuesday, June 14. On Thursday, March 31 the stock rating was downgraded by Cowen & Co to “Market Perform”. The company was downgraded on Wednesday, March 16 by Needham.
According to Zacks Investment Research, “Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 1.07 in Q2 2016. Its down 0.15, from 1.22 in 2016Q1. The ratio turned negative, as 8 funds sold all Achaogen Inc shares owned while 10 reduced positions. 10 funds bought stakes while 12 increased positions. They now own 13.87 million shares or 102.18% more from 6.86 million shares in 2016Q1.
Vanguard Grp holds 0% or 358,478 shares in its portfolio. Cqs Cayman Limited Partnership last reported 0.03% of its portfolio in the stock. Fmr Limited Co holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 2.62 million shares. The Illinois-based Northern has invested 0% in Achaogen Inc (NASDAQ:AKAO). Art Advsrs Ltd Llc holds 37,507 shares or 0.01% of its portfolio. Spark Mngmt Lc holds 0.01% or 15,100 shares in its portfolio. Goldman Sachs Grp Inc owns 25,731 shares or 0% of their US portfolio. Blackrock Fund Advsrs accumulated 41,882 shares or 0% of the stock. Geode Ltd Limited Liability Company owns 46,187 shares or 0% of their US portfolio. Point72 Asset Mgmt Limited Partnership accumulated 0.02% or 890,000 shares. Moreover, Morgan Stanley has 0% invested in Achaogen Inc (NASDAQ:AKAO) for 48,782 shares. State Bank Of America Corporation De accumulated 32,700 shares or 0% of the stock. Sphera Funds Mgmt Ltd has invested 1.24% of its portfolio in Achaogen Inc (NASDAQ:AKAO). Nomura Hldgs, a Japan-based fund reported 25,100 shares. Jacobs Levy Equity Mngmt Inc has 0% invested in the company for 62,572 shares.
Insider Transactions: Since September 27, 2016, the stock had 0 buys, and 2 selling transactions for $20,217 net activity. Sarpangal Zeryn also sold $4,597 worth of Achaogen Inc (NASDAQ:AKAO) on Tuesday, September 27. Wise Blake sold $15,620 worth of Achaogen Inc (NASDAQ:AKAO) on Tuesday, September 27.
More news for Achaogen Inc (NASDAQ:AKAO) were recently published by: Streetinsider.com, which released: “Form 4 Achaogen Inc For: Nov 18 Filed by: LOEB GARY” on November 24, 2016. Streetinsider.com‘s article titled: “Form 3 Achaogen Inc For: Nov 15 Filed by: LOEB GARY” and published on November 24, 2016 is yet another important article.
AKAO Company Profile
Achaogen, Inc., incorporated on November 26, 2002, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections, which include a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. The Company’s development plan for plazomicin includes over two Phase III clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.